Retrotope

13 articles with Retrotope

• Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)Company Exceeds Target Enrollment in Less Than Six Weeks; Data Readout Expected by End of 2021

  4/21/2021

  Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases, today announced that enrollment has been completed for its multicenter Phase 2 clinical trial evaluating RT001, the company’s lead development candidate, in patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease).

• Retrotope Announces Initiation of Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)

  3/17/2021

  Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases, today announced that the first patients have been dosed in a multicenter Phase 2 clinical trial evaluating RT001, the company’s lead development candidate, in patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease).

• Retrotope to Present at H.C. Wainwright Global Life Sciences Conference

  3/3/2021

  Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases, today announced that Anil Kumar, president and chief business officer, will deliver a corporate presentation as part of the H.C. Wainwright Global Life Sciences Conference.

• Retrotope Granted Rare Pediatric Disease Designation from FDA for Lead Development Candidate, RT001, in Two Life-Threatening Neurodegenerative Indications

  2/25/2021

  Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted two rare pediatric disease designations to RT001, the company’s lead development candidate.

• 

  BioSpace Movers & Shakers, Feb. 12

  2/12/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Retrotope Appoints Rick E Winningham as Chairman of Board of Directors in Advance of Key Clinical Trial Data Readouts

  2/11/2021

  Data Readout from Potentially Pivotal Phase 2/3 INAD Trial Expected 1H ‘01; Phase 2 ALS and Pivotal Phase 2/3 Friedreich’s Ataxia Trial Readouts Expected by Year-End

• US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the Treatment of Progressive SupraNuclear Palsy (PSP)

  2/18/2020

  Retrotope announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted orphan drug designation for its chemically-modified polyunsaturated fatty acid drug for the treatment of Progressive SupraNuclear Palsy.

• Retrotope Expands its Drug Pipeline with the First Dosing of RT001 in patients with Friedreich’s ataxia (FA)Three clinical trials centers now open for enrollment; two additional ones initiating

  1/9/2020

  Retrotope announced that it has dosed its first patient in a Phase 2/3 clinical trial of RT001 in Friedreich’s ataxia, the most common of the inherited ataxias.

• Parkinson’s Institute and Clinical Center and Retrotope Announce Collaboration on New Drug Treatment Therapies for Parkinson’s Disease Patients

  10/4/2018

  Parkinson’s Institute and Clinical Center and Retrotope announced today a collaboration on a new drug therapy to treat patients with Progressive SupraNuclear Palsy.

• 

  FDA Grants Orphan Drug Designation for Retrotope's RT001 in the Treatment of Phospholipase 2G6 (P...

  11/2/2017

  Physicians collaborating with Retrotope previously received approval from the FDA to test RT001 in Expanded Access trials of two patients having Infantile Neuroaxonal Dystrophy.

• Retrotope To Present First Human Data On Safety And Early Efficacy Of RT001 With Neurodegeneration At American Academy of Neurology Meeting

  4/25/2017

• Retrotope And Collaborators To Present Poster At American Academy of Neurology On Stabilized PUFA Drug Efficacy In Multiple Alzheimer’s Models

  4/25/2017

• Retrotope Announces Phase I/II Clinical Trial Results Of RT001 In Treatment Of Friedreich’s Ataxia

  9/16/2016